A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic and regimens as first-line therapy for advanced colorectal cancer

Annals of Oncology

Volumn 14, Issue 7, 2003, Pages 1106-1114

  Bouzid, Kamel ^a   Khalfallah, S ^b   Tujakowski, J ^c   Piko, B ^d   Purkalne, G ^e   Plate, S ^e   Padrik, P ^f   Serafy, M ^g   Pshevloutsky, E M ^h   Boussard, B ⁱ   Bapsy, P P ^j   Ahmed, S Ben ^j   Salek, T ^j   Doneo, S ^j   Gerges, D A ^j   Doval, D C ^j   Buyukunal, E ^j   Chernozemsky, I N ^j   Tzekova, V I ^j   El Azim, H A ^j   Errihani, H ^j   Samlali, R ^j   Godz, J S ^j   Ghilezan, N ^j   Berdov, B A ^j   Tchaikovsky, G N ^j   Wagnerova, M ^j   Aykan, N F ^j   Zidan, J ^j   Chachine, G ^j   more..

^a Centre Pierre et Marie Curie   (Algeria)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

^c Regional Oncology Centre Bydgoszcz   (Poland)

^d Pandy County Hospital   (Hungary)

^e RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^f UNIVERSITY OF TARTU   (Estonia)

^g NATIONAL CANCER INSTITUTE   (Egypt)

^h Oncology Dispanser   (Russian Federation)

ⁱ SANOFI   (France)

^j NONE

more..

Author keywords

5 fluorouracil folinic acid; Colorectal cancer; First line; Irinotecan

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; COTRIMOXAZOLE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BOLUS INJECTION; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; ORAL REHYDRATION THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0043202994     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg288     Document Type: Article

References (20)

1. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997; 80: 1179-1187.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
3. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-969.
4. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
5. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837-855.
6. Conti J, Kemeny N, Saltz L et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-715.
7. Pitot HC, Wender DB, O'Connell M et al. Phase II trial irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-2919.
8. Rougier P, Bugat R, Douillard J et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and pretreated patients with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260.
9. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518.
10. Rothenberg M, Eckardt J, Kuhn J et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-1135.
11. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35: 54-59.
12. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
13. Rougier P, Van Custem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
14. Saltz LB, Kanowitz J, Kemeny NE et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14: 2959-2967.
15. Rothenberg ML, Pazdur R, Rowinsky EK et al. A phase II multicenter trial of alternating cycles of irinotecan and 5-FU/LV in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 266a (Abstr 944).
16. Van Cutsem E, Pozzo, C, Starkhammar H et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998; 9: 1199-1204.
17. Vanhoefer U, Harstrick A, Köhne CH et al. Phase I study of a weekly schedule of irinotecan, high dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: 907-913.
18. Ducreux M, Ychou M, Seitz JF et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a dose finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999; 17: 2901-2908.
19. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
20. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.